Zobrazeno 1 - 1
of 1
pro vyhledávání: ''
Autor:
Ralf Gold, Aiden Haghikia, Maren Peschke, Gisa Ellrichmann, Kerstin Hellwig, De-Hyung Lee, Jan Bolz, Alexander Duscha, Ralf A. Linker
Publikováno v:
Journal of Neurology
Background With ocrelizumab another drug is available for the treatment of multiple sclerosis (MS). Little is known on the long-term use of ocrelizumab on immune cell subsets, and no surrogate markers are available. Rituximab (RTX) has been in off-la